Understanding Mechanisms of a-synuclein pathology

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Abstract

PROJECT SUMMARY - PROJECT 2: UNDERSTANDING MECHANISMS OF ? -SYNUCLEIN PATHOLOGY Genetic and biochemical abnormalities of ?-synuclein are directly implicated in the pathogenesis of familial and sporadic forms of Parkinson's disease (PD). The underlying mechanisms of ?-synuclein-induced neurodegeneration are poorly understood. Familial mutations in ?-synuclein as well as oxidative and nitrosative stress contribute to ?-synuclein pathology, in part, via enhanced oligomerization, fibrillation and aggregation. During the last funding cycle, we showed in collaboration with Project 1 that activation of the non- receptor tyrosine kinase, c-Abl may contributes to the pathogenesis of PD. From these studies emerged the exciting preliminary findings that c-Abl phosphorylates ?-synuclein at tyrosine 39. However, the potential roles of tyrosine 39 ?-synuclein and c-Abl activation in pathogenesis of PD has not been explored. We will study the roles of phosphorylation of ?-synuclein at tyrosine 39 and c-Abl activation in the death of DA neurons due to ?- synuclein, as well as, their roles in aggregation of ?-synuclein in vitro and in vivo. With the Proteomics Core D, the Clinical Core B and the Neuropathology Core C, we will investigate whether the levels of phosphorylation of ?-synuclein at tyrosine 39 can serve as a progression and/or pathologic maker of ?-synuclein-induced neurodegeneration and of ?-synuclein pathology in human PD. For these studies, we will assess the levels of tyrosine 39 phosphorylation of ?-synuclein and the activation state of c-Abl in human A53T ?-synuclein transgenic model, the adeno-associated virus-WT or A53T ?-synuclein model with DA neuron loss, and human post-mortem tissues from PD patients via a phosphospecific tyrosine 39 ?-synuclein antibody and MRM (Multiple Reaction Monitoring) mass spectrometry. Cell-to-cell transmission of misfolded ?-synuclein may contribute to the degeneration of DA neurons in sporadic PD and the mechanisms accounting for the recruitment and the corruption of endogenous ?-synuclein into fibrils are not known. Since our preliminary data suggests that tyrosine 39 phosphorylation of ?-synuclein by c-Abl promotes the fibrillation of ?-synuclein, we will study the ability of WT versus phospho-deficient Y39F and phospho-mimetic ?-synuclein Y39E, as well as c-Abl deficiency in cell-to-cell transmission and degeneration of DA neurons in the ?-synuclein PFF model of sporadic PD. Finally, we will explore proteomic changes induced by ?-synuclein PFFs in degenerating DA neurons via advanced spike-in mass spectrometry approaches combined with SILAM (Stable Isotope Labeling in Mammals). These studies will provide new mechanistic insights into the pathogenesis of ?-synuclein induced neurodegeneration and may lead to the development of novel therapeutic targets and biomarkers for the treatment of PD.